Earnings summaries and quarterly performance for NEOGEN.
Executive leadership at NEOGEN.
Board of directors at NEOGEN.
Research analysts who have asked questions during NEOGEN earnings calls.
BV
Brandon Vazquez
William Blair & Company, L.L.C.
6 questions for NEOG
Also covers: ALGN, CBLL, CVRX +16 more
David Westenberg
Piper Sandler
6 questions for NEOG
Also covers: ADPT, AKYA, BLLN +13 more
Subbu Nambi
Guggenheim Securities
3 questions for NEOG
Also covers: BOLD, BRKR, CARS +16 more
Tom DeBourcy
Nephron Research LLC
3 questions for NEOG
Also covers: CDNA, RGEN, TECH +2 more
BL
Bob Labick
CJS Securities
2 questions for NEOG
Also covers: ACVA, BCPC, BV +10 more
SN
Subhalaxmi Nambi
Guggenheim Securities
2 questions for NEOG
Also covers: AKYA, BRKR, CSTL +15 more
Thomas DeBourcy
Nephron Research
2 questions for NEOG
Also covers: CDNA, QTRX, TWST +2 more
Recent press releases and 8-K filings for NEOG.
Neogen Outlines Turnaround Strategy and Future Growth Plans
NEOG
Management Change
Guidance Update
New Projects/Investments
- Neogen's CEO Mike Nasif has rebuilt the entire management team with five external leaders, including a new CFO and Chief Science Officer, as part of a strategy to stabilize, accelerate, and expand the business.
- The company aims for mid to high single-digit top-line growth and adjusted EBITDA margins of 20% to 30%, with accelerated growth projected for fiscal year 2027.
- Following an overperformance in Q2, Neogen cautiously raised its guidance to restore predictable performance and rebuild trust.
- The new Petrifilm site in Lansing, Michigan, is on track to transfer all 17 SKUs from 3M by November 2026, and the company plans to increase R&D investment to accelerate innovation.
- The genomics division is the only planned divestiture, with an announcement expected later in the year.
1 day ago
NEOGEN Updates FY2026 Outlook and Details Strategic Plan
NEOG
Guidance Update
Management Change
New Projects/Investments
- NEOGEN has updated its FY2026 outlook, projecting Total Revenue between $845M-$855M and Adjusted EBITDA of approximately $175M.
- The company is executing a 3-phase plan (Stabilize, Accelerate, Expand) to restore consistent growth, targeting mid-single digit core revenue growth in the mid-term and aspiring to a 30% Adjusted EBITDA Margin at maturity.
- Executive leadership changes include Mike Nassif as President & CEO and Bryan Riggsbee as SVP, Chief Finance Officer, as part of efforts to rapidly transform Neogen.
- NEOGEN operates in Food Safety (72% of revenue, $5B addressable market) and Animal Safety (28% of revenue, $6B addressable market) with a total estimated addressable market of ~$11B.
1 day ago
Neogen Outlines Turnaround Strategy and Future Growth Plans
NEOG
Management Change
Guidance Update
M&A
- Neogen is implementing a three-stage turnaround strategy (stabilize, accelerate, expand) under a newly rebuilt management team, aiming for mid to high single-digit top-line growth and adjusted EBITDA margins of 20% to 30%.
- The company reported improved Q2 results, leading to a raised guidance, though management remains cautiously optimistic, emphasizing the need for predictable and sustainable performance.
- Key operational initiatives include the divestiture of its genomics division by the end of the fiscal year and the on-track development of a new Petrifilm site in Lansing, Michigan, with production transfer expected by November 2026.
- Neogen plans to increase investment in R&D to drive innovation, focusing on solving customer needs and expanding its portfolio, particularly with flagship products like Petrifilm.
1 day ago
Neogen Outlines Turnaround Strategy and Operational Updates
NEOG
Management Change
Guidance Update
M&A
- Neogen is implementing a three-stage turnaround strategy (stabilize, accelerate, expand) with the goal of achieving mid to high single-digit top-line growth and adjusted EBITDA margins of 20% to 30%.
- The company has rebuilt its entire management team, hiring five external leaders in the past five months, and reported improved Q2 results, which led to a raised guide.
- Construction of a standalone Petrifilm site in Lansing, Michigan, is on track, with the transfer of all 17 SKUs for production expected by November 2026.
- Neogen plans to divest its genomics division, with an announcement anticipated later in the year, as part of its focus on higher growth and more profitable markets.
- Innovation is a top priority, with plans to increase investment in R&D for tangible, differentiated, and scalable projects, and an investor day is planned for later in calendar year 2026.
1 day ago
Neogen Announces Q2 FY26 Results and Raises FY26 Guidance
NEOG
Earnings
Guidance Update
Management Change
- Neogen reported Q2 FY26 revenue of $224.7 million and Adjusted EBITDA of $48.7 million, marking a return to core growth of 2.9% year-over-year and a sequential improvement in Adjusted EBITDA margins of 470 basis points to 21.7%.
- The company raised its FY26 financial guidance, with total revenue now projected between $845 million and $855 million (up from $820M-$840M) and Adjusted EBITDA around $175 million (up from $165M-$175M).
- Strategic transformation efforts include key new management hires and a reduction in force of approximately 10% to align the cost structure, alongside an improvement in Free Cash Flow by $21 million compared to Q1.
8 days ago
Neogen Reports Strong Q2 2026 Results and Raises Full-Year Guidance
NEOG
Earnings
Guidance Update
Management Change
- Neogen reported Q2 2026 total revenues of $224.7 million, an increase of 2.9% on a core basis, and saw Adjusted EBITDA improve by 470 basis points sequentially to $48.7 million, representing a 21.7% margin.
- The company raised its full-year fiscal 2026 guidance, now expecting revenue in the range of $845 million-$855 million and Adjusted EBITDA of approximately $175 million.
- Strategic initiatives include cost structure improvements expected to deliver approximately $20 million in annualized savings, the ongoing process to divest its global genomics business with an announcement anticipated in Q4 of the current fiscal year, and the integration of Petrifilm remaining on track for Q2 fiscal 2027.
- Neogen also strengthened its leadership team with new hires, including a new CFO, Brian Rigsby, and Chief Commercial Officer, Joe Freels.
8 days ago
Neogen reports Q2 FY2026 results and raises full-year guidance
NEOG
Earnings
Guidance Update
Management Change
- Neogen reported Q2 FY2026 total revenues of $224.7 million, reflecting 2.9% core growth, and achieved adjusted EBITDA of $48.7 million, representing a 21.7% margin, which is a sequential improvement of 470 basis points from the first quarter.
- The company raised its full-year fiscal 2026 guidance, now expecting revenue in the range of $845 million-$855 million and adjusted EBITDA to be approximately $175 million.
- Neogen implemented cost structure improvements in Q2 FY2026, projected to deliver approximately $20 million in annualized savings, and saw improved production efficiency in its sample collection product line, which is expected to become a positive contributor to gross profit in the second half of the fiscal year.
- The integration of Petrifilm remains on track for the Q2 FY2027 timeline, with production testing and initial product validation showing encouraging results. Additionally, the divestiture of the global genomics business is progressing, with an announcement anticipated in Q4 FY2026.
- The leadership team was strengthened with new hires, including CFO Brian Rigsby and Chief Commercial Officer Joe Freels, among others, to accelerate innovation and execution excellence.
8 days ago
Neogen Reports Q2 FY 2026 Results and Raises Full-Year Guidance
NEOG
Earnings
Guidance Update
Management Change
- Neogen reported Q2 FY 2026 revenues of $224.7 million, an increase of 2.9% on a core basis, and adjusted EBITDA of $48.7 million, representing a 21.7% margin. Adjusted net income was $22.6 million, with adjusted EPS at $0.10.
- The company raised its full-year FY 2026 guidance, now projecting revenue between $845 million and $855 million and adjusted EBITDA of approximately $175 million.
- Strategic initiatives include cost structure improvements implemented in Q2, expected to yield approximately $20 million in annualized savings, and the Petrifilm integration remains on track for Q2 FY 2027.
- Neogen anticipates an announcement regarding the divestiture of its global genomics business in Q4 FY 2026, with net proceeds prioritized for debt reduction.
- The company has also strengthened its leadership team with new key hires, including a new CFO, Chief Commercial Officer, and other senior roles.
8 days ago
Neogen Announces Second-Quarter 2026 Results
NEOG
Earnings
Guidance Update
Demand Weakening
- Neogen reported revenue of $224.7 million for the second quarter ended November 30, 2025, marking a decrease of 2.8% year-over-year, although core growth increased by 2.9%.
- The company recorded a net loss of $15.9 million, or $(0.07) per diluted share, for Q2 2026. This is a significant improvement compared to the $456.3 million net loss in the prior-year period, which included a non-cash goodwill impairment charge that did not repeat. Adjusted Net Income for the quarter was $22.6 million.
- Adjusted EBITDA for the second quarter was $48.7 million, with an Adjusted EBITDA Margin of 21.7%.
- Neogen is raising its full-year fiscal 2026 outlook, with anticipated revenue in the range of $845 million to $855 million and Adjusted EBITDA expected to be approximately $175 million.
- As of November 30, 2025, the company held $145.3 million in cash and cash equivalents and had $800.0 million in total outstanding debt.
8 days ago
Neogen Announces Second-Quarter 2026 Results and Raises Full-Year Guidance
NEOG
Earnings
Guidance Update
Hiring
- Neogen reported Q2 FY 2026 revenue of $224.7 million, a 2.8% decrease year-over-year, though core growth increased by 2.9%.
- The company posted a net loss of $15.9 million (or $(0.07) per diluted share) but an Adjusted Net Income of $22.6 million (or $0.10 per diluted share) for the second quarter.
- Adjusted EBITDA was $48.7 million, representing an Adjusted EBITDA margin of 21.7% in Q2 FY 2026.
- Neogen is raising its full-year FY 2026 outlook, anticipating revenue in the range of $845 million to $855 million and Adjusted EBITDA of approximately $175 million.
- As of November 30, 2025, the company had $145.3 million in cash and cash equivalents and $800.0 million in total outstanding debt.
8 days ago
Quarterly earnings call transcripts for NEOGEN.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more